Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oragenics, Inc. (OGEN : AMEX)

• Company Description    Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $0.26 Daily Weekly Monthly 20 Day Moving Average: 488,912 shares Shares Outstanding: 116.39 (millions) Market Capitalization: $30.26 (millions) Beta: 0.12 52 Week High: $1.15 52 Week Low: $0.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -28.33% -21.48% 12 Week -33.71% -28.07% Year To Date -41.70% -30.68%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4902 EISENHOWER BOULEVARD SUITE 125 - TAMPA,FL 33634 USA ph: 813-286-7900 fax: 813-286-7904 tpatel@lhai.com http://www.oragenics.com

• General Corporate Information    Officers Michael O. Sullivan - Interim Principal Executive Officer and Chief Fina Frederick W. Telling - Chairman and Director Robert C. Koski - Director Charles L. Pope - Director Alan W. Dunton - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 684023302 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/15/22 Share - Related Items Shares Outstanding: 116.39 Most Recent Split Date: 1.00 (0.10:1) Beta: 0.12 Market Capitalization: $30.26 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.69 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -150.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -82.76% ROE 03/31/22 - -67.68 12/31/21 - -55.53 09/30/21 - -72.01 ROA 03/31/22 - -56.61 12/31/21 - -47.63 09/30/21 - -58.27 Current Ratio 03/31/22 - 15.37 12/31/21 - 19.17 09/30/21 - 13.90 Quick Ratio 03/31/22 - - 12/31/21 - 19.17 09/30/21 - 13.90 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -16,202.94 12/31/21 - -18,062.47 09/30/21 - - Book Value 03/31/22 - 0.15 12/31/21 - 0.20 09/30/21 - 0.22 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©